Gland Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Shyamakant Giri
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next
Nov 07
Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate
Oct 26Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet
Oct 01Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)
Sep 05Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 09Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?
Jun 22Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts
May 25Is Gland Pharma (NSE:GLAND) A Risky Investment?
Mar 19Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
Feb 16Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher
May 20Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 07Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers
Jul 22Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?
Jul 14Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?
Feb 08CEO
Shyamakant Giri
no data
Tenure
Mr. Shyamakant Giri is Chief Executive Officer of Gland Pharma Limited from January 15, 2025. Mr. Shyamakant Giri is President of India Business & Emerging Markets of Amneal Pharmaceuticals, Inc. from 2023...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.8yrs | ₹70.15m | no data | |
| Chief Financial Officer | 5.3yrs | ₹20.45m | no data | |
| Company Secretary & Vice-President of Compliance & CSR | no data | ₹6.05m | no data | |
| Chief Executive Officer | no data | no data | no data | |
| Chief Operating Officer | less than a year | no data | no data | |
| Head of Investments | 1.3yrs | no data | no data | |
| Head of Domestic Marketing | less than a year | no data | no data | |
| Head of Quality | less than a year | no data | 0.0012% ₹ 3.3m | |
| Senior Vice President of R&D | less than a year | no data | no data | |
| Chief Financial Controller | no data | no data | 0.000020% ₹ 53.8k |
0.8yrs
Average Tenure
51yo
Average Age
Experienced Management: GLAND's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.8yrs | ₹70.15m | no data | |
| Independent Director | 3.7yrs | ₹10.50m | no data | |
| Independent Director | 6.9yrs | ₹3.00m | no data | |
| Independent Director | 4.3yrs | ₹3.00m | no data | |
| Non-Executive and Non-Independent Director | less than a year | no data | no data | |
| Non-Independent Non Executive Director | 3.7yrs | no data | no data | |
| Independent Director | 6.2yrs | ₹3.00m | no data | |
| Non-Executive Non-Independent Director | less than a year | no data | no data |
4.0yrs
Average Tenure
60yo
Average Age
Experienced Board: GLAND's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 11:36 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gland Pharma Limited is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Neha Manpuria | BofA Global Research |